The estimated Net Worth of Mahkam Zanganeh is at least 1.59 百万$ dollars as of 26 March 2024. Dr Zanganeh owns over 110,321 units of Summit Therapeutics Inc stock worth over 1,135,000$ and over the last 8 years he sold SMMT stock worth over 0$. In addition, he makes 459,377$ as COO & Director at Summit Therapeutics Inc.
Dr has made over 15 trades of the Summit Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 110,321 units of SMMT stock worth 411,497$ on 26 March 2024.
The largest trade he's ever made was buying 23,527,044 units of Summit Therapeutics Inc stock on 8 March 2023 worth over 24,703,396$. On average, Dr trades about 791,433 units every 68 days since 2017. As of 26 March 2024 he still owns at least 50,000 units of Summit Therapeutics Inc stock.
You can see the complete history of Dr Zanganeh stock trades at the bottom of the page.
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA is the COO & Director at Summit Therapeutics Inc.
As the COO & Director of Summit Therapeutics Inc, the total compensation of Dr MBA at Summit Therapeutics Inc is 459,377$. There are no executives at Summit Therapeutics Inc getting paid more.
Dr MBA is 51, he's been the COO & Director of Summit Therapeutics Inc since . There are 5 older and 2 younger executives at Summit Therapeutics Inc. The oldest executive at Summit Therapeutics Inc is Robert W. Duggan, 77, who is the Co-CEO & Exec. Chairman.
Mahkam's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131.
Over the last 4 years, insiders at Summit Therapeutics Inc have traded over 0$ worth of Summit Therapeutics Inc stock and bought 529,946,601 units worth 632,334,967$ . The most active insiders traders include Robert W Duggan、Mahkam Zanganeh、Manmeet Singh Soni. On average, Summit Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of 751,966,329$. The most recent stock trade was executed by Mahkam Zanganeh on 26 March 2024, trading 110,321 units of SMMT stock currently worth 411,497$.
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Summit Therapeutics Inc executives and other stock owners filed with the SEC include: